SMC Global’s Shitij Gandhi: Buy Dr. Reddy’s for Rs 1,360 Target
SMC Global’s Senior Technical Analyst, Shitij Gandhi, advises traders to accumulate Dr. Reddy’s Laboratories stock for a target of Rs 1,360 in the next 5-7 weeks, following a strong technical breakout.
Dr ReddysStock MarketTechnical AnalysisPharmaceutical StocksInvestmentReal Estate NewsSep 11, 2025
Dr. Reddy’s Laboratories, a prominent player in the pharmaceutical industry, has shown robust performance in recent times. The stock’s technical indicators suggest a bullish trend, making it an attractive investment option for traders looking for short-term gains. Shitij Gandhi’s recommendation is based on the stock's technical setup, which includes a breakout from a consolidation phase, indicating potential upward momentum.
Pharmaceutical stocks, especially those with a strong global presence like Dr. Reddy’s, often attract investors due to their stable growth and consistent performance. The company’s diverse portfolio of products and its focus on research and development further bolster its market position. Dr. Reddy’s has been actively expanding its footprint in various markets, which is expected to drive its stock price higher.
Investors should, however, be cautious and consider the broader market conditions and any potential risks before making investment decisions. Technical analysis is a useful tool, but it should be complemented with fundamental analysis to make well-informed investment choices. Shitij Gandhi’s advice comes at a time when the Indian stock market is experiencing volatility, and investors are looking for stocks that can offer stability and growth.
In the current economic environment, pharmaceutical stocks are often seen as defensive plays, as they tend to perform well even in challenging market conditions. Dr. Reddy’s Laboratories, with its strong financials and strategic initiatives, is poised to benefit from the ongoing trends in the healthcare sector. Traders and investors alike should keep an eye on the stock’s performance and the broader market dynamics to capitalize on the opportunities it presents.
For those looking to invest in Dr. Reddy’s, it is recommended to set clear entry and exit points based on the technical analysis and to maintain a disciplined approach to risk management. The target of Rs 1,360, as suggested by Shitij Gandhi, provides a clear objective for traders to aim for in the coming weeks. As always, it is advisable to consult with a financial advisor before making any investment decisions.
Frequently Asked Questions
What is the target price for Dr. Reddy’s stock according to Shitij Gandhi?
Shitij Gandhi, Senior Technical Analyst at SMC Global Securities, recommends a target price of Rs 1,360 for Dr. Reddy’s stock in the next 5-7 weeks.
What is the basis for Shitij Gandhi’s recommendation?
Shitij Gandhi’s recommendation is based on the stock’s strong technical breakout on the daily charts after weeks of consolidation, indicating potential upward momentum.
Why are pharmaceutical stocks considered defensive plays?
Pharmaceutical stocks are often seen as defensive plays because they tend to perform well even in challenging market conditions, providing stability and growth.
What should investors consider before investing in Dr. Reddy’s stock?
Investors should consider the broader market conditions, the company’s financials, and the overall economic environment before investing in Dr. Reddy’s stock.
How can traders manage risk when following Shitij Gandhi’s advice?
Traders should set clear entry and exit points, maintain a disciplined approach to risk management, and consult with a financial advisor before making investment decisions.
Related News Articles
Wave Group to Launch 9,000 Flats in Wave City, Ghaziabad Amid Strong Housing Demand
Wave Group plans to launch 7 million square feet of premium and affordable housing in Wave City, Ghaziabad, with 8,000-9,000 apartments.
BMC Commissioner Stresses on PPP to Boost MMR Housing Stock
Mumbai: The BMC Commissioner, Bhushan Gagrani, highlights the need to create sufficient housing stock in the Mumbai Metropolitan Region (MMR) through public-private partnerships (PPP).
GujRERA Introduces QR Codes to Simplify Real Estate Project Information
The Gujarat Real Estate Regulatory Authority (GujRERA) has launched a new initiative effective October 1, incorporating Quick Response (QR) codes in all brochures and advertisements to provide buyers with easier access to project details.
Afcons Infra, a Shapoorji Pallonji Group Firm, to Launch Rs 5430 Crore IPO on October 25
Shapoorji Pallonji Group, a leading conglomerate with a diverse portfolio in real estate, water, energy, and financial services, is set to see one of its flagship companies, Afcons Infra, launch a significant IPO. The Rs 5430 crore IPO is scheduled to ope
Clarifying Capital Gains on Real Estate: Simplifying Acquisition and Reinvestment Dates
The article suggests that the Finance Minister should consider adding a clarification to treat the date of possession as the date of acquisition for under-construction properties under Sections 54 and 54F, to ease prolonged litigation.
Fox & Mandal Advises on Strategic Real Estate Joint Venture
Fox & Mandal, a leading law firm, provided comprehensive legal advice to Keventer and Adventz Finance on a significant joint venture in the real estate project development sector.